Organization
Ali Rezai
1 clinical trial
Clinical trial
Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients With With Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyStatus: Recruiting, Estimated PCD: 2029-07-01